首个软组织肉瘤单克隆抗体药物olaratumab

摘要

Olaratumab is an antibody against platelet-derived growth factor alpha receptor (PDGFR-α),the first monoclonal antibody against soft tissue sarcoma (STS).The FDA and EMA approved olaratumab to be used in combination with doxorubicin for STS patients with advanced histological subtypes,who are not suitable for radiotherapy and surgical treatment,but suitable for anthracycline treatment.In this paper,the status for treatment of STS,and the mechanism of action,pharmacokinetics,clinical research and safety of olaratumab were summarized.%olaratumab是一种血小板衍生生长因子受体α(PDGFR-α)阻断单克隆抗体,是首个针对晚期软组织肉瘤患者的单克隆抗体药物,与多柔比星联合应用于不适合放疗和手术治疗,但适合蒽环类治疗的晚期组织学亚型软组织肉瘤(soft tissue sarcomas,STS)患者.olaratumab通过加速评审,分别于2016年10月19日和2016年11月9日通过美国FDA和欧盟EMA批准上市.本文对STS治疗现状以及该药的作用机制、药动学、临床研究、安全性等进行综述.